European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a blank-check company that filed its S-1 with the SEC on February 17, 2021, targeting acquisition opportunities in the European biotechnology and life sciences sector. The vehicle went public in 2021 during a period of elevated activity among healthcare-focused SPACs and was structured to identify businesses operating across biotechnology, pharmaceuticals, and adjacent life sciences verticals, with a deliberate emphasis on the European market. EBAC represents one of a cohort of geographically specialized blank-check vehicles that emerged in the first half of 2021. For current deal status, shareholder filings, and sponsor details on EBAC, sign up for full data access at SpacDesk.